Phosphatidylinositol 3-kinase (PI3K)/AKT pathway alterations are some of the most common genomic alterations identified in breast cancer, and recently, the FDA granted approval of PI3Kα-specific inhibitor alpelisib plus fulvestrant in PIK3CA-altered ER-positive metastatic breast cancer [19]. Here, PIK3CA is linked to breast carcinoma.